Engrail Therapeutics nabs $32m Series A

San Diego-based Engrail Therapeutics, a drug developer, has raised $32 million in Series A financing.

18 June 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles